Romosozumab + Teriparatide for Osteoporosis (CAT Trial)

Palo Alto (17 mi)

Overseen byBenjamin Leder, MD

Age: 18+

Sex: Female

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Massachusetts General Hospital

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Eligibility Criteria

This trial is for postmenopausal women aged 45 and older who have osteoporosis with a high risk of fractures. Participants should not have used bone health treatments significantly before, nor should they have other bone diseases, serious kidney or liver issues, heart/lung problems, psychiatric disorders, abnormal calcium levels, severe vitamin D deficiency, anemia or a history of cancer (except skin cancer). They also shouldn't abuse alcohol or substances.

Inclusion Criteria

I am a woman aged 45 or older.

I have gone through menopause.

I have osteoporosis with a high risk of breaking bones.

Exclusion Criteria

I haven't used significant bone health treatments.

I have a bone condition that is not osteoporosis.

I have had cancer before, but not skin cancer.

I am allergic or react badly to romosozumab or teriparatide.

Treatment Details

The study is examining the effects of two FDA-approved medications for treating postmenopausal osteoporosis: Romosozumab and Teriparatide. It aims to understand how these drugs work in managing the condition and preventing fractures.

2Treatment groups

Active Control

Group I: RomosozumabActive Control1 Intervention

romosozumab

Group II: Romosozumab and TeriparatideActive Control2 Interventions

romosozumab and teriparatide